BALCX
Price
$36.31
Change
-$0.05 (-0.14%)
Updated
Nov 13 closing price
MTRBX
Price
$20.97
Change
+$0.02 (+0.10%)
Updated
Nov 13 closing price
Ad is loading...

BALCX vs MTRBX

Header iconBALCX vs MTRBX Comparison
Open Charts BALCX vs MTRBXBanner chart's image
American Funds American Balanced C
Price$36.31
Change-$0.05 (-0.14%)
VolumeN/A
CapitalizationN/A
MFS Total Return B
Price$20.97
Change+$0.02 (+0.10%)
VolumeN/A
CapitalizationN/A
BALCX vs MTRBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
BALCX vs. MTRBX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BALCX is a StrongBuy and MTRBX is a Buy.

FUNDAMENTALS
Fundamentals
BALCX has more cash in the bank: 240B vs. MTRBX (8.1B). MTRBX (1.60) and BALCX (1.59) have matching dividends . BALCX was incepted earlier than MTRBX: BALCX (24 years) vs MTRBX (31 years). BALCX is a more actively managed with annual turnover of: 171.00 vs. MTRBX (43.00). BALCX has a lower initial minimum investment than MTRBX: BALCX (250) vs MTRBX (1000). BALCX annual gain was more profitable for investors over the last year : 23.86 vs. MTRBX (15.59). BALCX return over 5 years is better than : 33.79 vs. MTRBX (12.30).
BALCXMTRBXBALCX / MTRBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years31 years-
Gain YTD15.02910.565142%
Front LoadN/AN/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets240B8.1B2,963%
Annual Yield % from dividends1.591.6099%
Returns for 1 year23.8615.59153%
Returns for 3 years10.30-5.32-194%
Returns for 5 years33.7912.30275%
Returns for 10 years47.4628.57166%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTVT13.910.98
+7.58%
vTv Therapeutics
STBA43.22-0.19
-0.44%
S&T Bancorp
VMI345.23-3.06
-0.88%
Valmont Industries
BIDU84.80-3.48
-3.94%
Baidu
TCRX5.43-0.27
-4.74%
TScan Therapeutics